Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.
  • Page:
  • 1
  • 2
  • 3
  • 4

Oxford Biomedica Keeps going Up (OXB)     

apple - 10 Dec 2003 15:45

draw?scheme=Colourful&epic=OXBdraw?scheme=Colourful&size=Medium&showVodraw?scheme=Colourful&showVolume=true&stdraw?scheme=Colourful&size=Medium&showVo



Almost Day after day, this keeps going up.

What happens is there are lots of small shareholders selling out during the day who probably bought in when it was 25p due to being tipped in shares mag in July

THEN

At the end of each day there is a really BIG BUY that most people don't notice.
Usually at 16:29.

Next morning, it usually opens up 1/4p

This keeps on happening.

I finally freed up some cash this morning & bought some.
I wish that I had got in at 17p.

The big buyers obviously think that the new drugs will ge a great success.

What do you think?


It was also tipped again in October

SHARES MAGAZINE 30-10-2003

The gene therapy specialist has had a good run this year with shares rising to 28.2p in September. The company has two cancer therapies in the clinic for a range of indications as well as early-stage drugs for neurological disorders.

TroVax is a revolutionary cancer vaccine that works by delivering a gene to the cancer cell via a pox virus acting as a Trojan horse. The drug is in Phase II trials in colorectal cancer patients with the kudos of being sponsored by Cancer Research UK and trials in breast and renal cancer patients. MetXia has also received approval to enter Phase I/II trials for pancreatic cancer.

Investors should recall the high failure rate of cancer drugs such as British Biotechs Marimastat and remember that the risks are high, but Oxford Biomedica is well funded following a recent fundraising and there is still everything to play for.

http://www.wallstreetreporter.com/profiles/OxfordBioMedica.html

Ultimate Cynic - 03 Mar 2004 16:13 - 74 of 79

Managad to sell my extra 5,400 when the price blipped up yesterday which enabled me to buy back 5,000 GFM. First time I've been able to catch a price blip like that. Still holding my original 10,000 though - won't let those go!
I really want this company to suceed and beat this terrible disease once and for all then we can all breathe a sigh of relief.

DSTOREY9916 - 03 Mar 2004 22:16 - 75 of 79

I am a recent buyer of this stock. Like all buyers of stock we do so in the hope of making money, period. But I am looking at OXB with higher aim and that is the hope that they can actually pull it off and go a long way to beating cancer! So for the first time I am going long not only because I will make money and I say that with no shame, but I also strongly believe in rationale and the aim of the company and its products for the good of all.
Best wishes to all, Dave.

Janus - 04 Mar 2004 08:14 - 76 of 79

Oxford BioMedica has prescription to strike gold

It is a dream of every company manager: instead of having to find the cash to develop a potential multi-million pound bestselling product, along comes a charity or government to pay the investment for you.

The dream has come true not once, but repeatedly for Alan Kingsman, chief executive of Oxford BioMedica. The company is working on science so exciting that Cancer Research UK and the US National Cancer Institute are bankrolling big human trials of TroVax, a vaccine for colorectal and breast cancer. They don't want a thing in return, not even royalties on any product. "They just want to cure cancer," says Professor Kingsman.

The things that have drawn these organisations to OXB might scare some investors away: the science is revolutionary and unproven. There might be nothing here at the end of the day. But if it does get proven, OXB could be sitting on a goldmine.

The company, which had 31.8m in the bank at the end of 2003, will spend up to 12m of its own cash a year to fund other trials of TroVax and MetXia, a gene therapy cancer treatment. Many programmes are behind schedule, but the breadth of the portfolio means OXB is at least a prolific generator of news, which ultimately drives share prices in this highly speculative sector.




http://news.independent.co.uk/business/investment_column/story.jsp?story=497610

apple - 08 Mar 2004 09:36 - 77 of 79

Another share where the MMs appear to be gathering stock.

Mostly selling this morning but the price goes up.

The MMs must have an idea that good news is coming soon.

robstuff - 11 Mar 2004 10:32 - 78 of 79

Super opp to pick these up cheap today, as no bad news, just down on the back of the market, mms taking advantage of the nervous profit takers - why do we always panic when the dow drops?!

tbrooking66 - 11 Mar 2004 10:54 - 79 of 79

There are some rumours of another lisencing deal on the cards. Maybe this is the reason for MM investment here?
  • Page:
  • 1
  • 2
  • 3
  • 4
Register now or login to post to this thread.